Por motivos de mantenimiento se ha deshabilitado el inicio de sesión temporalmente. Rogamos disculpen las molestias.
Artículo
Dysfunction in the Cystic Fibrosis Transmembrane Regulator in Chronic Obstructive Pulmonary Disease as a Potential Target for Personalised Medicine
Autor/es | Carrasco Hernández, Laura
Quintana Gallego, María Esther Calero Acuña, Carmen Reinoso Arija, Rocío Ruiz Duque, Borja López-Campos Bodineau, José Luis |
Departamento | Universidad de Sevilla. Departamento de Medicina |
Fecha de publicación | 2021-10-10 |
Fecha de depósito | 2022-11-04 |
Publicado en |
|
Resumen | In recent years, numerous pathways were explored in the pathogenesis of COPD in the quest for new potential therapeutic targets for more personalised medical care. In this context, the study of the cystic fibrosis transmembrane ... In recent years, numerous pathways were explored in the pathogenesis of COPD in the quest for new potential therapeutic targets for more personalised medical care. In this context, the study of the cystic fibrosis transmembrane conductance regulator (CFTR) began to gain importance, especially since the advent of the new CFTR modulators which had the potential to correct this protein’s dysfunction in COPD. The CFTR is an ion transporter that regulates the hydration and viscosity of mucous secretions in the airway. Therefore, its abnormal function favours the accumulation of thicker and more viscous secretions, reduces the periciliary layer and mucociliary clearance, and produces inflammation in the airway, as a consequence of a bronchial infection by both bacteria and viruses. Identifying CFTR dysfunction in the context of COPD pathogenesis is key to fully understanding its role in the complex pathophysiology of COPD and the potential of the different therapeutic approaches proposed to overcome this dysfunction. In particular, the potential of the rehydration of mucus and the role of antioxidants and phosphodiesterase inhibitors should be discussed. Additionally, the modulatory drugs which enhance or restore decreased levels of the protein CFTR were recently described. In particular, two CFTR potentiators, ivacaftor and icenticaftor, were explored in COPD. The present review updated the pathophysiology of the complex role of CFTR in COPD and the therapeutic options which could be explored. |
Cita | Carrasco Hernández, L., Quintana Gallego, M.E., Calero Acuña, C., Reinoso Arija, R., Ruiz Duque, B. y López-Campos Bodineau, J.L. (2021). Dysfunction in the Cystic Fibrosis Transmembrane Regulator in Chronic Obstructive Pulmonary Disease as a Potential Target for Personalised Medicine. Biomedicines, 9 (10), 1437. https://doi.org/10.3390/biomedicines9101437. |
Ficheros | Tamaño | Formato | Ver | Descripción |
---|---|---|---|---|
Dysfunction in the Cystic Fibrosis ... | 1.144Mb | [PDF] | Ver/ | |